Putting this up for argument rather than for agreement. I have read it twice and I am still not certain what it supports.
The pattern that distinguishes a bad batch from an exit is behaviour rather than product. A bad batch comes with communication, a reshipment offer and a batch number. An exit comes with slower replies, pressure toward less reversible payment methods, sudden discounting, and the same reassurance repeated without any new information. The product tells you less than the correspondence does.
Where I think it is weakest: the completion rate deserves as much attention as the headline, because a large effect among those who finished is a different claim from a large effect among those enrolled.
What would genuinely help is knowing how people are distinguishing a supplier having a bad batch from a supplier on the way out. Practical detail welcome, however dull — the duller the better.
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
Dr.ObesityMed said:The pattern that distinguishes a bad batch from an exit is behaviour rather than product.
Dr.ObesityMed has the substance of this right. The condition it depends on is worth stating. The useful checklist is about verifiability rather than presentation. Independent test results commissioned by buyers rather than by the seller, consistency across multiple batches over time rather than one flattering report, a physical address and a company registration that resolve, batch and lot numbers on the actual labelling, and a shipping practice that matches what the material needs. Everything a good-looking website provides is cheap to fake; none of the items above are.
Dr.ObesityMed said:The pattern that distinguishes a bad batch from an exit is behaviour rather than product.
I disagree that testing history is decisive. It tells you what a supplier did when they were being watched. Continuity of behaviour under stress — a late shipment, a failed test, a complaint — is more predictive than any run of good results.
Janoshik Analytical — Independent Testing
Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.
Verify Your PeptidesGL Biochem (Shanghai) Ltd. — Direct Manufacturer
Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.
Browse GL BiochemShort answer first, then the reasoning. Prices dramatically below market are the strongest single signal, and the reason is arithmetic rather than suspicion. Synthesis, testing, and cold-chain shipping have floors. A price well under the floor means something was skipped, and the two things that get skipped are testing and content.
LibrarianMeg said:The useful checklist is about verifiability rather than presentation.
This matches mine closely enough to be worth saying so out loud. The detail I would add is minor and it is already implied above.